Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-11-15
    E.g., 2018-11-15

Articles

9185 items
10:58 AM, Oct 25, 2018  |  BC Innovations | Distillery Therapeutics

Autoimmune disease; neurology

INDICATION: Multiple sclerosis (MS); Alzheimer’s disease (AD) Mouse studies suggest a mAb against fibrin could help treat MS and AD. In a mouse model of chronic MS and two mouse models of relapsing-remitting MS (RRMS),...
10:58 AM, Oct 25, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Breast Cancer Patient sample, cell culture and mouse studies suggest inhibiting ANKLE2 could help treat breast cancer. In breast cancer patients, high tumor levels of ANKLE2 were associated with disease progression and poor overall...
10:58 AM, Oct 25, 2018  |  BC Innovations | Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary fibrosis Patient sample, cell culture and mouse studies suggest inhibiting STAT3 or immune checkpoint inhibitors could help treat idiopathic pulmonary fibrosis (IPF) or sarcoidosis-associated pulmonary fibrosis. In IPF patients, lung levels of PD-1 and...
10:57 AM, Oct 25, 2018  |  BC Innovations | Distillery Therapeutics

Infectious disease

INDICATION: Coronavirus; influenza virus; HIV/AIDS; Ebola Cell culture and rat studies identified lipopeptide-based inhibitors of MERS-CoV S protein, Ebola virus glycoprotein and HIV env that could help treat Middle East respiratory syndrome coronavirus (MERS-CoV), Ebola virus,...
11:45 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Dermatology

INDICATION: Scars/wrinkles Patient sample and mouse studies suggest inhibiting CXCL12 could help treat scars. In injured skin samples from scar patients, CXCL12 levels were higher in patients aged 40 years or younger with thick scars than...
11:45 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Musculoskeletal

INDICATION: Muscular dystrophy Patient sample, cell culture and mouse studies suggest inhibiting CB1 could help treat Duchenne muscular dystrophy (DMD). In quadriceps tissue samples from pediatric DMD patients, CB1 expression levels were higher than in...
11:44 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Cell culture and mouse studies suggest inhibiting CASP1 could help treat AD. In primary human neurons overexpressing APP, a tool compound CASP1 inhibitor decreased axon degeneration compared with no treatment. In a...
11:43 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Musculoskeletal; autoimmune disease

INDICATION: Osteoporosis; arthritis Mouse studies suggest inhibiting miR-182 could help treat osteoporosis and arthritis. In a mouse model of estrogen deficiency-induced osteoporosis, myeloid lineage osteoclast precursor-specific knockout of miR-182 or chitosan nanoparticles loaded with an antisense...
11:43 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample and mouse studies suggest inhibiting Notch 1 could help treat metastatic medulloblastoma. In primary tumor samples from medulloblastoma patients, levels of Notch 1 were higher in patients with metastases than in...
11:41 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Stroke Mouse studies suggest the selective GABA re-uptake inhibitor tiagabine could help treat neonatal hypoxic brain injury. In a neonatal mouse model of hypoxia-induced brain injury, tiagabine decreased the percentage of missteps, a measure of...

Pages